ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
FloatingCity
|
151 |
32K |
12 |
08/06/24 |
08/06/24 |
ASX - By Stock
|
151
|
32K
|
12
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
FloatingCity
|
510 |
117K |
2 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
510
|
117K
|
2
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
FloatingCity
|
510 |
117K |
6 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
510
|
117K
|
6
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
FloatingCity
|
510 |
117K |
5 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
510
|
117K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Pipeline-in-a-drug
|
|
FloatingCity
|
61 |
10K |
10 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
61
|
10K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
FloatingCity
|
151 |
32K |
2 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
151
|
32K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
FloatingCity
|
151 |
32K |
9 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
151
|
32K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
FloatingCity
|
151 |
32K |
3 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
151
|
32K
|
3
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
FloatingCity
|
510 |
117K |
13 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
510
|
117K
|
13
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
FloatingCity
|
510 |
117K |
6 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
510
|
117K
|
6
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
FloatingCity
|
10K |
4.8M |
7 |
22/05/24 |
22/05/24 |
ASX - By Stock
|
10K
|
4.8M
|
7
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
FloatingCity
|
510 |
117K |
11 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
510
|
117K
|
11
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
FloatingCity
|
510 |
117K |
10 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
510
|
117K
|
10
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
FloatingCity
|
510 |
117K |
4 |
20/05/24 |
20/05/24 |
ASX - By Stock
|
510
|
117K
|
4
|
|
ASX - By Stock
|
CYC |
Re:
Ann: Cyclopharm Business Update
|
|
FloatingCity
|
8 |
2.6K |
2 |
20/05/24 |
20/05/24 |
ASX - By Stock
|
8
|
2.6K
|
2
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
FloatingCity
|
510 |
117K |
10 |
20/05/24 |
20/05/24 |
ASX - By Stock
|
510
|
117K
|
10
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
FloatingCity
|
510 |
117K |
11 |
20/05/24 |
20/05/24 |
ASX - By Stock
|
510
|
117K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust appoints Sergio Duchini as Non-Executive Chairman
|
|
FloatingCity
|
58 |
16K |
12 |
20/05/24 |
20/05/24 |
ASX - By Stock
|
58
|
16K
|
12
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
FloatingCity
|
1.0K |
537K |
1 |
20/05/24 |
20/05/24 |
ASX - By Stock
|
1.0K
|
537K
|
1
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
FloatingCity
|
510 |
117K |
4 |
20/05/24 |
20/05/24 |
ASX - By Stock
|
510
|
117K
|
4
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
FloatingCity
|
510 |
117K |
3 |
20/05/24 |
20/05/24 |
ASX - By Stock
|
510
|
117K
|
3
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
FloatingCity
|
510 |
117K |
13 |
20/05/24 |
20/05/24 |
ASX - By Stock
|
510
|
117K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust receives Orphan Drug Designation for monepantel
|
|
FloatingCity
|
43 |
12K |
10 |
18/05/24 |
18/05/24 |
ASX - By Stock
|
43
|
12K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust receives Orphan Drug Designation for monepantel
|
|
FloatingCity
|
43 |
12K |
20 |
18/05/24 |
18/05/24 |
ASX - By Stock
|
43
|
12K
|
20
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust receives Orphan Drug Designation for monepantel
|
|
FloatingCity
|
43 |
12K |
8 |
18/05/24 |
18/05/24 |
ASX - By Stock
|
43
|
12K
|
8
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
FloatingCity
|
510 |
117K |
14 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
510
|
117K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor update
|
|
FloatingCity
|
86 |
20K |
18 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
86
|
20K
|
18
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor update
|
|
FloatingCity
|
86 |
20K |
8 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
86
|
20K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor update
|
|
FloatingCity
|
86 |
20K |
9 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
86
|
20K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor update
|
|
FloatingCity
|
86 |
20K |
9 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
86
|
20K
|
9
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
FloatingCity
|
510 |
117K |
3 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
510
|
117K
|
3
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
FloatingCity
|
510 |
117K |
6 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
510
|
117K
|
6
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
FloatingCity
|
510 |
117K |
3 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
510
|
117K
|
3
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
FloatingCity
|
510 |
117K |
8 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
510
|
117K
|
8
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
FloatingCity
|
510 |
117K |
12 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
510
|
117K
|
12
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
FloatingCity
|
510 |
117K |
4 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
510
|
117K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor update
|
|
FloatingCity
|
86 |
20K |
6 |
16/05/24 |
16/05/24 |
ASX - By Stock
|
86
|
20K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust to test MPL effectiveness on Alzheimer's and Parkinson's
|
|
FloatingCity
|
42 |
9.4K |
6 |
15/05/24 |
15/05/24 |
ASX - By Stock
|
42
|
9.4K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust to test MPL effectiveness on Alzheimer's and Parkinson's
|
|
FloatingCity
|
42 |
9.4K |
9 |
15/05/24 |
15/05/24 |
ASX - By Stock
|
42
|
9.4K
|
9
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
FloatingCity
|
1.4K |
359K |
10 |
15/05/24 |
15/05/24 |
ASX - By Stock
|
1.4K
|
359K
|
10
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
FloatingCity
|
1.4K |
359K |
8 |
15/05/24 |
15/05/24 |
ASX - By Stock
|
1.4K
|
359K
|
8
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
FloatingCity
|
1.4K |
359K |
11 |
15/05/24 |
15/05/24 |
ASX - By Stock
|
1.4K
|
359K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust to test MPL effectiveness on Alzheimer's and Parkinson's
|
|
FloatingCity
|
42 |
9.4K |
6 |
14/05/24 |
14/05/24 |
ASX - By Stock
|
42
|
9.4K
|
6
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
FloatingCity
|
1.4K |
359K |
3 |
14/05/24 |
14/05/24 |
ASX - By Stock
|
1.4K
|
359K
|
3
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
FloatingCity
|
1.4K |
359K |
3 |
13/05/24 |
13/05/24 |
ASX - By Stock
|
1.4K
|
359K
|
3
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
FloatingCity
|
1.4K |
359K |
7 |
13/05/24 |
13/05/24 |
ASX - By Stock
|
1.4K
|
359K
|
7
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
FloatingCity
|
1.4K |
359K |
2 |
13/05/24 |
13/05/24 |
ASX - By Stock
|
1.4K
|
359K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Board Changes
|
|
FloatingCity
|
250 |
62K |
7 |
12/05/24 |
12/05/24 |
ASX - By Stock
|
250
|
62K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Board Changes
|
|
FloatingCity
|
250 |
62K |
11 |
11/05/24 |
11/05/24 |
ASX - By Stock
|
250
|
62K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Board Changes
|
|
FloatingCity
|
250 |
62K |
5 |
11/05/24 |
11/05/24 |
ASX - By Stock
|
250
|
62K
|
5
|
|